Update on invasive opportunistic mycoses: Clinical trials review, 2008–2009
- Andreas H. Groll
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Invasive fungal infections remain major causes for morbidity and mortality in severely ill or immunocompromised patients. The past decade saw major expansion in the antifungal armamentarium, and the precise role of newer antifungal agents continues to be defined through clinical trials. This article summarizes five of the most relevant clinical trials related to prevention and treatment of opportunistic fungal infections in adult patients published between 2008 and 2009.
- Betts RF, Nucci M, Talwar D, et al.; Caspofungin High-Dose Study Group: A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48:1676–1684. CrossRef
- Groll AH, Mickiene D, Petraitiene R, et al.: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001, 45:2845–2855. CrossRef
- Maertens J, Raad I, Petrikkos G, et al.; Caspofungin Salvage Aspergillosis Study Group: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563–1571. CrossRef
- Herbrecht R, Maertens J, Baila L, et al.: Caspofungin as first-line therapy of invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients: a study of the EORTC Infectious Diseases Group [abstract M2167]. Presented at the American Society for Microbiology 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25–27, 2008.
- Labelle AJ, Micek ST, Roubinian N, Kollef MH: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008, 36:2967–2972. CrossRef
- Schuster MG, Edwards JE Jr, Sobel JD, et al.: Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008, 149:83–90.
- Cornely OA, Maertens J, Winston DJ, et al.: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348–359. CrossRef
- Ullmann AJ, Lipton JH, Vesole DH, et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335–347. CrossRef
- Rijnders BJ, Cornelissen JJ, Slobbe L, et al.: Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008, 46:1401–1408. CrossRef
- Pascual A, Calandra T, Bolay S, et al.: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201–211. CrossRef
- Update on invasive opportunistic mycoses: Clinical trials review, 2008–2009
Current Infectious Disease Reports
Volume 11, Issue 6 , pp 417-419
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Andreas H. Groll (1)
- Author Affiliations
- 1. Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, Children’s University Hospital, Albert-Schweitzer-Strasse 33, 48129, Münster, Germany